Company intelligence / Profile preview

Cobalis

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Cobalis has advanced its lead product, PreHistin, an allergy prevention medication based on cyanocobalamin, into Phase 3 clinical trials. The company aims to secure FDA approval to market PreHistin as an over-the-counter medication in the United States. Clinical results have positioned PreHistin as a promising solution for allergy sufferers by addressing unmet needs in atopic disease management.

Therapeutic areas: PulmonologyDermatologyImmunologyNeurology
Modalities: Small moleculeVitamin derivative
Industry: Biotech

Drug pipeline

1 asset

PreHistin

Unknown

Partnerships

Melodic Distribution Company (MDC), for international distribution of PreHistinClinDatrix, contract research organization for Phase III trials

Beyond the preview

Go deeper on Cobalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cobalis.

Explore the full profile